Effect of alpha-lipoic acid at the combination with mefenamic acid in girls with primary dysmenorrhea: randomized, double-blind, placebo-controlled clinical trial

Yousefi, Mojgan; Kavianpour, Maria; Hesami, Sepideh; Nooshabadi, Mohammadreza Rashidi; Haghighian, Hossein Khadem

doi:10.1080/09513590.2019.1590544

Cited by 3 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The copyright holder for this this version posted August 9, 2022. ; https://doi.org /10.1101/2022.08.08.22278399 doi: medRxiv preprint chronic pelvic pain associated with endometriosis reported greater efficacy in reducing pain when administered in combination with other compounds (35). Continuous treatment and treatment on the days before menstruation have shown positive results in reducing pain (35,36). A case report describes that administration of Br (2000 mg/day changing to 3000 mg/day 3 days before menses) in combination with other compounds and acupuncture significantly reduced pain (from 8 to 2 on the VAS scale) (37).…”

Section: Discussionmentioning

confidence: 99%

Study of the recommended dosage of the N-Acetyl Cysteine, Alpha Lipoic Acid, Bromelain and Zinc preparation as a treatment for dysmenorrhea

Estrada¹,

Carmona

2022

Preprint

View full text Add to dashboard Cite

Dysmenorrhea, defined as pain during menstruation, is the most common gynecological condition, affecting a large percentage of women with varying degrees of pain. In recent years, the management of dysmenorrhea has become increasingly important because of the emotional, health and economic burden it entails and because of the need for new studies and research for effective treatments to alleviate its symptoms. The most common treatments for dysmenorrhea are NSAIDs or oral contraceptives, although gynecologists also recommend the preparation composed of N-acetyl cysteine (NAC), alpha lipoic acid (LA), bromelain (Br) and Zinc (Zn), (NAC/LA/Br/Zn) due to its anti-inflammatory and anti-oxidative properties and efficacy in reducing pain. However, there is no data on what dosage of the preparation should be recommended for patients with dysmenorrhea. Therefore, the aim of this study is to determine how the NAC/LA/Br/Zn preparation is recommended for the treatment of dysmenorrhea in daily clinical practice and what specialists base their decision on. A survey was conducted among gynecologists with extensive experience recommending the preparation, with a participation rate of 97% (N=73). The most frequently recommended regimen is to begin with continuous administration for 90 days with 10-day breaks (69%) or without breaks (31%). Specialists recommend the preparation for any type of pain and may recommend discontinuous administration (in the days around menstruation) when the pain is moderate or mild. In patients with primary dysmenorrhea with mild pain, the most recommended approach is discontinuous therapy in the days around menstruation (50.7%) followed by continuous administration for 90 days with 10-day breaks (24.7%). When pain is moderate or severe, the most recommended approach is 90-day continuous therapy with 10-day breaks (47.9% and 71.2%, respectively). In the case of secondary dysmenorrhea, the most recommended approach is 90-day continuous therapy with 10-day breaks for any degree of pain (41.1%, 57.5% and 76.7% for mild, moderate and severe pain, respectively). Most gynecologists (79%) adapt the regimen after clinical assessment of the degree of pain towards discontinuous administration patterns, on the days around menstruation. Most of the specialists consulted do not modify the recommended regimen if the patient is being treated with other drugs such as NSAIDs, hormonal contraception or a combination of progestogens (78%, 59% and 58%, respectively). The preparation is recommended in conjunction with hygienic-dietary measures without modification of the dosage (90%). This is the first study that addresses how specialists recommend the NAC/LA/Br/Zn preparation to patients with dysmenorrhea. The most common regimen for dysmenorrhea is to start treatment with continuous administration of the preparation for 90 days with 10 days of break, continuing the regimen or adapting it according to the degree of pain reported by the patient during treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Study of the recommended dosage of the N-Acetyl Cysteine, Alpha Lipoic Acid, Bromelain and Zinc preparation as a treatment for dysmenorrhea

Estrada¹,

Carmona

2022

Preprint

View full text Add to dashboard Cite

show abstract

“…In this ruler, the first score is considered painless and the last one is assumed as severe pain. According to this scale, the participants are divided into groups of painless (0), mild (1-3), moderate (4-7), and severe pain (8)(9)(10). Scores above 3 were considered as PD.…”

Section: Methodsmentioning

confidence: 99%

“…The proinflammatory cytokines such as tumor necrosis factor-alpha (TNFα), interleukin 1 (IL1), and interleukin 6 (IL6) increase the production of prostaglandins in the uterine which makes the uterus to have frequent contractions and leads to typical pain of PD. 3,8 Although, taking medications such as nonsteroidal anti-inflammatory drugs (NSAIDs) has been identified as the first line treatment of PD, but long-term use of it is associated with several side effects. Therefore, researchers are trying to find a new and safer treatment for dysmenorrhea compared to NSAIDS.…”

Section: Introductionmentioning

confidence: 99%

Decreased dysmenorrhea pain in girls by reducing oxidative stress and inflammatory biomarkers following supplementation with oleoylethanolamide: A randomized controlled trial

Kazemi

Lalooha

Nooshabadi

et al. 2022

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Aim This study aimed to evaluate the oleoylethanolamide (OEA) effects on oxidative stress and inflammatory factors in girls with primary dysmenorrhea. Methods This double‐blind, placebo‐controlled clinical trial was done on population consisted of female students who had dysmenorrhea pain based on the visual analogue scale (VAS) questionnaire. Patients were randomly allocated to groups consuming a capsule containing 125 mg of OEA per day (n = 22) or placebo (n = 22) for 2 months. The severity of the pain, total antioxidant capacity (TAC), malondialdehyde (MDA), C‐reactive protein (CRP), and tumor necrosis factor alpha (TNF‐α) were measured at the beginning and the end of the study. In this study, SPSS software was used to analyze the data. Results According to the results, oral supplementation with OEA for 60 days significantly increased TAC (p = 0.022) and decreased the menstrual pain (p = 0.040), MDA (p = 0.011), CRP (p = 0.01), and TNF‐α (p = 0.038) compared to the placebo group. Also, intragroup changes were statistically significant on the mean of pain (p = 0.042), TAC (p = 0.032), MDA (p = 0.023), CRP (p = 0.027), and TNF‐α (p = 0.029) at the end of the study in the intervention group. Changes in the studied factors at the end of the study compared to the beginning of the study in the placebo group were not statistically significant. Conclusion Considering the reducing effects of OEA on menstrual pain, using of this supplement can be introduced as an alternative medicine to reduce the use of anti‐inflammatory drugs.

show abstract

Nutritional practices to manage menstrual cycle related symptoms: a systematic review

Brown,

Martin,

Waldron

et al. 2023

Nutr. Res. Rev.

View full text Add to dashboard Cite

Certain nutritional practices may reduce menstrual-related symptoms, but there is no current consensus on what foods/supplements are sufficiently evidenced to warrant promotion to reduce menstrual symptoms of naturally menstruating individuals. This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Two online databases were searched for published experimental studies that investigated the effects of foods/supplements on menstrual-related symptoms in eumenorrheic women. Extracted data and study characteristics were tabulated and grouped based on food/supplement intervention and dosage compared to UK dietary reference values (DRVs) and safe upper limits. In total, 28 studies and 21 different foods/supplement interventions were included in the review. None of the studies reported a negative effect on symptoms, 23 reported a positive effect and 5 had no effect. Eighteen different ways of measuring menstrual-related symptoms were described across the studies. The results indicate a lack of consistency in studies to confidently provide information to eumenorrheic, naturally menstruating women regarding the use of foods/supplements to reduce menstrual symptoms. Determination of menstrual-related symptoms varied along with dose and duration of food or supplements provided. These data provide some evidence for the use of vitamin D, calcium, zinc and curcumin to reduce menstrual related symptoms of non-hormonal contraceptive users, on an individual basis, however further investigation is required prior to implementation with a focus on robust protocols to determine and measure changes in menstrual symptoms, with interventions adhering to DRVs and safe upper limits.

show abstract

Effect of alpha-lipoic acid at the combination with mefenamic acid in girls with primary dysmenorrhea: randomized, double-blind, placebo-controlled clinical trial

Cited by 3 publications

References 27 publications

Study of the recommended dosage of the N-Acetyl Cysteine, Alpha Lipoic Acid, Bromelain and Zinc preparation as a treatment for dysmenorrhea

Study of the recommended dosage of the N-Acetyl Cysteine, Alpha Lipoic Acid, Bromelain and Zinc preparation as a treatment for dysmenorrhea

Decreased dysmenorrhea pain in girls by reducing oxidative stress and inflammatory biomarkers following supplementation with oleoylethanolamide: A randomized controlled trial

Nutritional practices to manage menstrual cycle related symptoms: a systematic review

Contact Info

Product

Resources

About